Health: Development of factories "Vacra" To achieve optimal exploitation of productive and human energies
The Ministry of Health and Population announced the development and raising of the efficiency of the existing factories at the headquarters of the Holding Company for Biomedics and Vaccines & quot; & quot; This is to achieve the optimal exploitation of the productive energies and human energies owned by the company, as well as cooperation with the world leading companies in the field of vaccine production to introduce new products and enrich the company’s products package, which had a great impact in securing the needs of the Ministry of Health and Population. Paxera according to the recommendations of the WHO experts, which is intended to fill in the Lyophilized vaccines and liquid, and contributes to covering a large percentage of vaccination needs in the country to the Ministry of Health and Population with a production capacity (100) million doses annually on an area of (710) square meters, in addition to the building factory (1), where the efficiency of the production areas, the water station and the system have been developed and raised The HVAC, which is dedicated to the production of lifetime vaccine for lifeing antsera, from the initial stages to the final stages, which is one of the basic treatments in cases of snake bites, scorpions, and life with a production capacity (3) million doses annually on an area of (2435) square meters
& nbsp;
and indicated & quot; Abdul Ghaffar & quot; To develop and raise the efficiency of the productive areas of the (2) building factory according to the latest GMP requirements, which is intended for the production of biological products from the insulin and rabies vaccine vaccine & nbsp; A production capacity of 3 million doses annually on an area of 1090 square meters, in addition to the presence of a cooling room complex that includes & nbsp; 96 refrigerated rooms with a size of 1000 square meters, dedicated to keeping the vaccines and vaccines in a safe way through electronic control systems for continuous temperature monitoring & nbsp; With a capacity of 60 million doses, it is subject to good manufacturing requirements. The raw plasma production sector has been developed, and the places of experiments in Helwan, which is one of the most important pillars supporting the production of vaccines and vaccines, and contributes greatly to saving the lives of citizens who are exposed to snakes, scorpions and life, in addition to supporting the veterinary sector, and promoting animal health through the development of the veterinary industry by signing a technology transfer contract, and joint cooperation with the Canadian Corveda company in the field of production of preparations Veterinary. Annually, in cooperation with the Indian company Fabetics, in addition to establishing 8 production control laboratories equipped with the latest devices for measuring production quality in its various stages, and the creation of the logistical central cooling complex on an area & nbsp; 3180 square meters through a grant from the Chinese Sinovac company by implementing the Chinese company CSCEC, one of the largest construction companies globally, with a capacity of 150 million doses, with the aim of increasing the storage capacity of vaccines in the Arab Republic Vaccine Settlement, Akkad & quot; Elephant & quot; It is underway with the world leading companies in the field of vaccine production to introduce new products and enrich the company’s products package, which has had a great impact in securing the needs of the Ministry of Health and Population, where several vaccines and vaccines were provided from the Indian Sirm Institute, including the five -year vaccine, the triple vaccine, a senior hepatitis B vaccine, titanus tucchid vaccine, a dual school vaccine, a MR vaccine, and a MR vaccine MR, in addition to a delegation from the Korean Green Cross company visited Egypt to agree to implement the stages of the transfer technology contract. On communicating with a number of companies that have products that have the approval of the World Health Organization to sign manufacturing technology transfer contracts with the aim of participating in the African Union initiative to provide 60% of the continent’s needs of human vaccines manufactured locally by 2040.
